Verona Pharma plc is a UK-based biopharmaceutical company focused on developing and commercializing therapies for chronic respiratory diseases.
Its lead product, ensifentrine (Ohtuvayre), is an inhaled, selective dual phosphodiesterase 3 and 4 (PDE3/PDE4) inhibitor approved in 2024 in the United States for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The molecule provides both bronchodilator and non-steroidal anti-inflammatory effects and is being evaluated for additional respiratory indications, including non-cystic fibrosis bronchiectasis.
None yet. When a new project in the record names Verona Pharma as owner, partner or investor, it shows here.
Q1 revenue $16.3B; KEYTRUDA $8.0B. GAAP loss $1.72/sh, non-GAAP loss $1.28/sh after $9.0B Cidara charge. Announced Terns acquisition; raised 2026 sales to $65.8-67.0B and non-GAAP EPS $5.04-5.16
Strong oncology and animal health sales, positive trial results, and strategic acquisitions drive growth. 2026 outlook projects sales up to $67B, with EPS impacted by acquisition charges.
Sales rose 4% to $17.3B. KEYTRUDA up 10%, GARDASIL down 24%. GAAP EPS $2.32, Non-GAAP $2.58. FDA approved KEYTRUDA QLEX. Acquired Verona Pharma. Full-year sales outlook: $64.5B-$65B.
Merck enhances its cardio-pulmonary portfolio with Ohtuvayre, a novel COPD treatment, following the $10 billion acquisition of Verona Pharma.
